gluctam mr 30 mg tablete s prirejenim sproščanjem
servier pharma d.o.o. - gliklazid - tableta s prirejenim sproščanjem - gliklazid 30 mg / 1 tableta - gliklazid
kvetiapin lek 50 mg tablete s podaljšanim sproščanjem
lek d.d. - kvetiapin - tableta s podaljšanim sproščanjem - kvetiapin 50 mg / 1 tableta - kvetiapin
remirta 45 mg orodisperzibilne tablete
actavis group ptc ehf. - mirtazapin - orodisperzibilna tableta - mirtazapin 45 mg / 1 tableta - mirtazapin
concordina 10 mg/5 mg tablete
merck d.o.o. - amlodipin; bisoprolol - tableta - amlodipin 5 mg / 1 tableta bisoprolol8,49 mg / 1 tableta; bisoprolol 8,49 mg / 1 tableta - bisoprolol in amlodipin
concordina 5 mg/10 mg tablete
merck d.o.o. - amlodipin; bisoprolol - tableta - amlodipin 10 mg / 1 tableta bisoprolol4,24 mg / 1 tableta; bisoprolol 4,24 mg / 1 tableta - bisoprolol in amlodipin
concordina 5 mg/5 mg tablete
merck d.o.o. - amlodipin; bisoprolol - tableta - amlodipin 5 mg / 1 tableta bisoprolol4,24 mg / 1 tableta; bisoprolol 4,24 mg / 1 tableta - bisoprolol in amlodipin
tysabri
biogen netherlands b.v. - natalizumab - multiple skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
versiguard rabies
zoetis belgium rue laid burniat 1 1348 louvain -
alphaflorovet
alpha -
cotellic 20 mg filmsko obložene tablete
roche registration gmbh - kobimetinib - filmsko obložena tableta - kobimetinib 20 mg / 1 tableta - kobimetinib